STOCK TITAN

Opko Health (OPK) Financials

OPK NASDAQ
Trailing 12 months to September 30, 2026
Revenue $501.6M -8.3% YoY
Net Income -$148.1M n/m YoY
EPS (Diluted) -$0.19 n/m YoY
Free Cash Flow -$135.3M n/m YoY
Market Cap $1.2B as of Nov 20, 2026
Price / Sales 2.3x on $501.6M revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 1.0x on $1.1B equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the OPK SEC filings page.

Opko Health Inc. (OPK) reported $501.6M in revenue over the twelve months to Sep 30, 2026, down 8.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI OPK FY2025

OPKO’s shrinking sales base still demands substantial operating investment, leaving a cash-consuming business despite very low debt.

Revenue fell 14.9% in FY2025, yet operating cash flow remained an outflow of $179M, exposing weak cash conversion. That mismatch means the smaller top line did not translate into proportionately lower cash needs, even as capital spending fell 50.9%.

Gross margin expanded to 33.9% in FY2025 while operating margin remained negative at -19.4%, indicating better gross economics did not cover the full operating cost base. SG&A fell 26.7%, but R&D rose 17.9%, so cost reduction was selective rather than broad-based.

Long-term debt was $2M versus total liabilities of $664M, making debt a minor funding source. A 4.0x current ratio alongside a 24.0% fall in current liabilities points to less short-term balance-sheet pressure, even while operations remained cash negative.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 41 / 100
Financial Health Score 41/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Opko Health Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
23

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Opko Health Inc. scores 23/100 on it among other operating companies.

Growth
6

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Opko Health Inc. scores 6/100 on it among other operating companies.

Leverage
94

Opko Health Inc. carried $0.00 of long-term debt for every $1 of shareholders' equity at the end of fiscal year 2025, a debt-to-equity ratio of 0.00. With no positive EBITDA in fiscal year 2025, Opko Health Inc. is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 94/100 among other operating companies measured the same way.

Liquidity
87

Opko Health Inc. held $3.97 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 3.97. Liquidity ranks operating companies on that ratio, and Opko Health Inc. scores 87/100 among other operating companies.

Cash Flow
8

Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Opko Health Inc. scores 8/100 on it among other operating companies.

Returns
28

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Opko Health Inc. scores 28/100 on it among other operating companies.

Altman Z-Score Distress
-0.22

Opko Health Inc. scores -0.22, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $2.3B against total assets of $1.9B. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral
4/9

Opko Health Inc. passes 4 of 9 financial strength tests. 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.

Earnings Quality No Cash Backing
N/A

Opko Health Inc. reported a net loss of $225.7M while operations used $178.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$65.4M
YoY+15.9%
QoQ-60.0%
5Y CAGR-29.9%
10Y CAGR-13.2%

Opko Health Inc. generated $65.4M in revenue in Q3 2026. This represents an increase of 15.9% from the same quarter a year earlier. Against the prior quarter it is down 60.0%.

EBITDA
-$8.7M
YoYn/m
QoQ-156.2%

Opko Health Inc.'s EBITDA was -$8.7M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 156.2%.

Net Income
-$53.5M
YoY-347.5%
QoQn/m
10Y CAGRn/m

Opko Health Inc. reported a net loss of $53.5M in Q3 2026. This represents a decrease of 347.5% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.07
YoY-333.3%
QoQn/m

Opko Health Inc. earned -$0.07 per diluted share (EPS) in Q3 2026. This represents a decrease of 333.3% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
-$39.1M
YoYn/m
QoQn/m
10Y CAGRn/m

Opko Health Inc. recorded an outflow of $39.1M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$384.0M
YoY-6.8%
QoQ+27.7%
5Y CAGR+20.9%
10Y CAGR+10.3%

Opko Health Inc. held $384.0M in cash against $1.6M in long-term debt as of Q3 2026.

Shares Outstanding
743M
YoY-3.3%
QoQ-0.5%
5Y CAGR+1.7%
10Y CAGR+2.9%

Opko Health Inc. had 743M shares outstanding in Q3 2026. This represents a decrease of 3.3% from the same quarter a year earlier. Against the prior quarter it is down 0.5%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
64.3%
YoY+2.2pp
QoQ+15.4pp

Opko Health Inc.'s gross margin was 64.3% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 2.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 15.4 percentage points.

Operating Margin
-48.0%
YoY+11.4pp
QoQ-43.8pp

Opko Health Inc.'s operating margin was -48.0% in Q3 2026, reflecting core business profitability. This is up 11.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 43.8 percentage points.

Net Margin
-81.8%
YoY-120.2pp
QoQ-76.7pp
5Y change-89.3pp
10Y change-73.6pp

Opko Health Inc.'s net profit margin was -81.8% in Q3 2026, showing the share of revenue converted to profit. This is down 120.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 76.7 percentage points.

Return on Equity
-4.8%
YoY-6.5pp
QoQ-4.1pp
5Y change-6.4pp
10Y change-3.7pp

Opko Health Inc.'s quarterly ROE was -4.8% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 6.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.1 percentage points.

Capital Allocation

R&D Spending
$32.2M
YoY+8.0%
QoQ-3.0%

Opko Health Inc. invested $32.2M in research and development in Q3 2026. This represents an increase of 8.0% from the same quarter a year earlier. Against the prior quarter it is down 3.0%.

Share Buybacks
$10.6M
YoY-30.4%
QoQ-18.3%

Opko Health Inc. spent $10.6M on share buybacks in Q3 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 30.4% from the same quarter a year earlier. Against the prior quarter it is down 18.3%.

Capital Expenditures
$2.8M
YoY-11.1%
QoQ-7.3%
5Y CAGR-17.4%
10Y CAGR-3.9%

Opko Health Inc. invested $2.8M in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 11.1% from the same quarter a year earlier. Against the prior quarter it is down 7.3%.

OPK Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OPK quarterly income statement
MetricQ3'2610-QQ2'2610-Q/AQ1'2610-Q/AQ4'2510-KQ3'2510-QQ2'2510-Q/AQ1'2510-Q/AQ4'2410-K
Revenue$65.4M+15.9%$163.6M+4.3%$124.2M-17.2%$148.5M-19.2%$56.4M-67.5%$156.8M-13.9%$150.0M-13.7%$183.6M+1.0%
Cost of Revenue$23.4M+9.2%$83.6M-22.2%$78.4M-26.9%N/A$21.4M-84.0%$107.4M-17.7%$107.3M-18.5%N/A
Gross Profit$42.1M+20.0%$80.0M+62.0%$45.8M+7.4%N/A$35.1M-12.7%$49.4M-4.4%$42.6M+1.3%N/A
R&D Expenses$32.2M+8.0%$33.2M+9.3%$29.2M-5.3%N/A$29.8M+3.6%$30.3M+26.0%$30.8M+40.6%N/A
SG&A Expenses$24.8M+11.5%$52.9M-11.2%$48.6M-17.7%N/A$22.3M-77.3%$59.6M-13.4%$59.1M-15.8%N/A
Operating Income-$31.4Mn/m-$7.0Mn/m-$51.0Mn/mN/A-$33.6Mn/m-$60.0Mn/m-$67.2Mn/mN/A
EBITDA-$8.7Mn/m$15.4Mn/m-$28.8Mn/mN/A-$10.8Mn/m-$37.0Mn/m-$43.7Mn/mN/A
Interest Expense$13.5M+18.8%$11.4M-83.8%$10.9M-29.3%N/A$11.3M-34.8%$70.3M+759.7%$15.5M+101.2%N/A
Income Tax-$7.3Mn/m-$5.0Mn/m-$6.1Mn/mN/A-$8.1M-134.2%-$14.1Mn/m-$5.8Mn/mN/A
Net Income-$53.5M-347.5%-$8.4Mn/m-$54.8Mn/m-$31.3M-322.8%$21.6M-13.1%-$148.4Mn/m-$67.6Mn/m$14.0Mn/m
EPS (Basic)-$0.07-333.3%-$0.01n/m-$0.07n/m-$0.04-300.0%$0.03-25.0%-$0.19n/m-$0.10n/m$0.02n/m
EPS (Diluted)-$0.07-333.3%-$0.01n/m-$0.07n/m-$0.04-500.0%$0.030.0%-$0.19n/m-$0.10n/m$0.01
Diluted Shares (Avg)746M-3.9%755M-4.2%759M+13.0%N/A777M-22.2%788M+13.0%672MN/A

OPK Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OPK quarterly balance sheet
MetricQ3'2610-QQ2'2610-Q/AQ1'2610-Q/AQ4'2510-QQ3'2510-QQ2'2510-QQ1'25FilingQ4'2410-K
Total Assets$1.9B-5.8%$1.8B-7.3%$1.9B-12.8%$1.9B-12.2%$2.0B-11.6%$2.0B-0.3%$2.1B+7.8%$2.2B+9.4%
Current Assets$806.3M+28.6%$500.2M-14.2%$535.4M-27.4%$581.9M-12.1%$627.1M-0.4%$583.3M+63.0%$737.6M+88.5%$662.1M+113.9%
Cash & Equivalents$384.0M-6.8%$300.8M+12.5%$331.9M-22.6%$364.4M-14.6%$412.0M+3.0%$267.3M+558.7%$428.8M+466.9%$426.6M+344.9%
Inventory$50.6M-22.1%$61.9M-6.8%$64.4M+0.6%$52.7M-7.2%$65.0M+9.3%$66.3M+10.3%$64.0M+7.8%$56.8M-13.5%
Accounts Receivable$80.2M-15.2%$81.9M-17.6%$79.6M-17.2%$90.3M-23.5%$94.6M-11.3%$99.4M-5.6%$96.2M-13.7%$118.0M-4.3%
Long-Term Investments$44.5M+232.9%$40.2M+208.3%$10.5M-17.4%$14.2M-74.0%$13.4M-86.7%$13.0M-87.1%$12.8M-68.9%$54.6M+239.4%
Goodwill$317.4M-34.4%$481.5M-0.6%$482.3M+1.2%$320.8M-39.4%$484.0M-9.7%$484.2M-8.7%$476.7M-10.2%$529.3M-11.5%
Total Liabilities$764.1M+10.7%$645.3M-4.6%$652.2M-20.1%$664.0M-20.5%$690.0M-19.1%$676.1M+15.7%$816.7M+13.2%$834.8M+34.1%
Current Liabilities$162.4M-4.1%$149.4M-12.7%$148.4M-49.8%$146.7M-24.0%$169.3M-20.0%$171.2M-22.0%$295.9M+44.8%$193.1M-3.5%
Non-Current Liabilities$601.7M+15.6%$495.9M-1.8%$503.8M-3.3%$517.3M-19.4%$520.7M-18.8%$504.9M+38.3%$520.8M+0.8%$641.7M+51.9%
Long-Term Debt$1.6M-37.7%$1.8M-35.8%$2.0M-29.2%$2.3M-24.7%$2.5M-28.9%$2.8M-24.6%$2.8M-29.8%$3.0M-61.1%
Total Equity$1.1B-14.5%$1.2B-8.7%$1.2B-8.2%$1.3B-7.1%$1.3B-7.0%$1.3B-7.1%$1.3B+4.7%$1.4B-1.7%
Retained Earnings-$2.4Bn/m-$2.4Bn/m-$2.3Bn/m-$2.3Bn/m-$2.3Bn/m-$2.3Bn/m-$2.1Bn/m-$2.1Bn/m

Not reported in any period shown, so not listed: Short-Term Investments.

OPK Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OPK quarterly cash flow statement
MetricQ3'2610-QQ2'2610-Q/AQ1'2610-Q/AQ4'2510-KQ3'2510-QQ2'2510-Q/AQ1'2510-Q/AQ4'2410-K
Operating Cash Flow-$36.3Mn/m-$43.5Mn/m-$19.3Mn/m-$25.9Mn/m-$34.6Mn/m-$83.4Mn/m-$34.6Mn/m-$44.4Mn/m
Depreciation & Amortization$22.7M-0.1%$22.4M-2.7%$22.2M-5.5%$22.4M-6.9%$22.7M-5.9%$23.0M-4.7%$23.5M-9.0%$24.0M-7.5%
Stock-Based Compensation$1.8M-40.0%$2.2M0.0%$2.7M+4.5%N/A$3.0M+7.1%$2.2M-15.4%$2.6M+1.0%N/A
Capital Expenditures$2.8M-11.1%$3.0M-8.5%$1.8M-42.6%$2.7M-50.7%$3.1M-60.5%$3.3M-54.5%$3.2M-28.1%$5.4M+79.1%
Free Cash Flow-$39.1Mn/m-$46.5Mn/m-$21.1Mn/m-$28.6Mn/m-$37.8Mn/m-$86.7Mn/m-$37.7Mn/m-$49.8Mn/m
Investing Cash Flow$11.3M-94.2%$15.5Mn/m-$1.8M-104.4%-$2.0M-101.8%$194.6M-21.4%-$2.8Mn/m$40.5Mn/m$116.0Mn/m
Financing Cash Flow$114.5Mn/m-$13.0Mn/m-$5.2Mn/m-$18.3Mn/m-$16.2M-107.9%-$79.5Mn/m-$4.0M-119.5%-$40.5Mn/m
Share Buybacks$10.6M-30.4%$13.0M-28.7%$4.8Mn/m$13.5M-18.0%$15.3M-35.7%$18.3Mn/m$0-100.0%$16.5Mn/m

Not reported in any period shown, so not listed: Dividends Paid.

OPK Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OPK quarterly financial ratios
MetricQ3'2610-QQ2'2610-Q/AQ1'2610-Q/AQ4'2510-KQ3'2510-QQ2'2510-Q/AQ1'2510-Q/AQ4'2410-K
Gross Margin64.3%+2.2pp48.9%+17.4pp36.8%+8.4ppN/A62.1%+39.0pp31.5%+3.2pp28.4%+4.2ppN/A
Operating Margin-48.0%+11.4pp-4.3%+34.0pp-41.1%+3.7ppN/A-59.5%-20.8pp-38.3%-4.4pp-44.8%-3.6ppN/A
Net Margin-81.8%-120.2pp-5.1%+89.5pp-44.2%+0.9pp-21.1%-28.7pp38.3%+24.0pp-94.7%-89.0pp-45.1%+2.0pp7.6%+44.2pp
Return on Equity-4.8%-6.5pp-0.7%+10.7pp-4.5%+0.6pp-2.5%-3.5pp1.7%-0.1pp-11.5%-10.7pp-5.1%+1.4pp1.0%+5.8pp
Return on Assets-2.9%-3.9pp-0.5%+7.1pp-2.9%+0.2pp-1.6%-2.3pp1.1%0.0pp-7.5%-7.0pp-3.2%+1.0pp0.6%+3.9pp
Current Ratio4.97+1.3x3.35-0.1x3.61+1.1x3.97+0.5x3.70+0.7x3.41+1.8x2.49+0.6x3.43+1.9x
Debt-to-Equity0.000.0x0.000.0x0.000.0x0.000.0x0.000.0x0.000.0x0.000.0x0.000.0x
Liabilities-to-Equity0.68+0.2x0.540.0x0.54-0.1x0.52-0.1x0.53-0.1x0.52+0.1x0.620.0x0.61+0.2x
Asset Turnover0.030.0x0.090.0x0.070.0x0.080.0x0.030.0x0.080.0x0.070.0x0.080.0x
FCF Margin-59.8%+7.2pp-28.4%+26.9pp-17.0%+8.1pp-19.3%+7.9pp-67.0%-18.0pp-55.3%-36.8pp-25.2%-2.1pp-27.1%-4.4pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Opko Health Inc. OPK FY2025 $606.9M -$225.7M -37.2% $1.2B 41/100
Castle Biosciences, Inc. CSTL FY2025 $344.2M -$24.2M -7.0% $1.0B 61/100
Personalis, Inc. PSNL FY2025 $69.6M -$81.3M N/A $1.5B 52/100
GeneDx Holdings Corp. WGS FY2025 $427.5M -$21.0M -4.9% $1.4B 48/100
NeoGenomics, Inc. NEO FY2025 $727.3M -$108.0M -14.8% $1.9B 50/100
Fulgent Genetics, Inc. FLGT FY2025 $322.7M -$60.5M -18.8% $673.9M 45/100

Frequently Asked Questions

Opko Health Inc. (OPK) reported $606.9M in total revenue for fiscal year 2025. This represents a -14.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Opko Health Inc. (OPK) revenue declined by 14.9% year-over-year, from $713.1M to $606.9M in fiscal year 2025.

No, Opko Health Inc. (OPK) reported a net loss of $148.1M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $225.7M, with a net profit margin of -37.2%.

Opko Health Inc. (OPK) reported diluted earnings per share of -$0.30 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Opko Health Inc. (OPK) had EBITDA of -$25.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Opko Health Inc. (OPK) had $364.4M in cash and equivalents against $2.3M in long-term debt.

Opko Health Inc. (OPK) had a gross margin of 33.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Opko Health Inc. (OPK) had an operating margin of -19.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Opko Health Inc. (OPK) had a net profit margin of -37.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Opko Health Inc. (OPK) has a return on equity of -17.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Opko Health Inc. (OPK) recorded an outflow of $190.8M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Opko Health Inc. (OPK) recorded an outflow of $178.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Opko Health Inc. (OPK) had $1.9B in total assets as of fiscal year 2025, including both current and long-term assets.

Opko Health Inc. (OPK) invested $12.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Opko Health Inc. (OPK) invested $124.0M in research and development during fiscal year 2025.

Yes, Opko Health Inc. (OPK) spent $47.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Opko Health Inc. (OPK) had 759M shares outstanding as of fiscal year 2025.

Opko Health Inc. (OPK) had a current ratio of 3.97 as of fiscal year 2025, which is generally considered healthy.

Opko Health Inc. (OPK) had a debt-to-equity ratio of 0.00 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Opko Health Inc. (OPK) had a liabilities-to-equity ratio of 0.52 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Opko Health Inc. (OPK) had a return on assets of -11.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Opko Health Inc. (OPK) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $1.2B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Opko Health Inc. (OPK) trades at 2.3x sales, its market capitalization divided by $501.6M revenue, trailing 12 months to September 30, 2026. The market capitalization is $1.2B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Opko Health Inc. (OPK) has an Altman Z-Score of -0.22, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Opko Health Inc. (OPK) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Opko Health Inc. (OPK) reported a net loss of $225.7M while operations used $178.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Opko Health Inc. (OPK) scores 41 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top